Biotech Updates

Genetically Engineered Dendritic Cells Improve Immunotherapy Against Lung Cancer

April 3, 2024

Researchers from the University of California, Los Angeles (UCLA) suggest that genetically engineered dendritic cells could improve stronger immune responses against lung cancer. This method enhances the effectiveness of a type of immunotherapy called immune checkpoint blockade. Their study is published in Cell.

Checkpoint blockade immunotherapy is a treatment for cancer that uses immune checkpoint inhibitors to keep the body's immune system strong and enhance its ability to fight off cancer cells. However, this treatment poses challenges to many patients as they experience disease progression after initial response.

Scientists found that high amounts of chemokines, specifically CXCL9 and CXCL10, can help the immune system fight against cancer. Hence, researchers from UCLA genetically engineered dendritic cells to produce CXCL9 and CXCL10 and directly injected these into the tumors. The researchers found that this method increased the number of T cells and slowed down the growth of tumors.

For more information, read the journal article from Cell.

You might also like: